The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related
mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous …

Background Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown
antitumour activity in advanced hepatocellular carcinoma, but few studies of VEGFR …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in
unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

Purpose To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and
oxaliplatin) administered as palliative chemotherapy to patients with advanced …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor
prognosis. The incidence of HCC and HCC-related deaths have increased over the last …